Bioventix Plc (LON:BVXP) has been reiterated to Corporate in a statement by finnCap earlier today.
- Updated: September 17, 2016
finnCap has reiterated Bioventix Plc(LON:BVXP) to Corporate in a statement released on 8/22/2016.
On Monday March 21 2016, finnCap reported about Bioventix Plc(LON:BVXP) bumped the target price from 1,040.00GBX to 1,250.00GBX. At the time, this indicated a possible upside of 0.09%.
Yesterday Bioventix Plc (LON:BVXP) traded 0.00% even at 975.00GBX. BVXP’s 50-day moving average is 1,056.19GBX and its two hundred day average is 1,038.05GBX. With the last stock price close down 8.38% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. Volume of trade was was down over the average, with 10,536 shares of BVXP changing hands under the typical 13,611 shares..
Bioventix Plc has a 52 week low of 899.50GBX and a one-year high of 1,324.25GBX with a PE ratio of 20. BVXP’s total market value is presently 0.0 GBX.
About Bioventix Plc (LON:BVXP)
Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company uses its technology in the fields of clinical diagnostics. Its develops products for Thyroid, Fertility, Oncology, Vitamin D, Drugs of Abuse and other diseases. Its product, and Vitamin D SMA is a steroid hormone involved in the intestinal absorption of calcium and the regulation of calcium homeostasis but it has also evolved into a hormone that has a diversity of biologic effects.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.